Lipocine Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $190.1K | $119.4K | $1.1M | $114.6K | $622.8K | $93.9K | $89.6K | $7.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $2.0M | $2.8M | $2.7M | $2.7M | $2.1M | $1.1M | $1.9M | $2.8M |
| SG&A Expense | $991.0K | $1.2M | $983.4K | $767.8K | $890.4K | $1.1M | $1.5M | $1.6M |
| Operating Income | $-2.8M | $-3.8M | $-2.5M | $-3.4M | $-2.4M | $-2.1M | $-3.3M | $3.2M |
| Operating Margin | -1,495.1% | -3,224.1% | -219.6% | -2,933.5% | -386.0% | -2,226.8% | -3,676.2% | 42.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-2.6M | $-3.7M | $-2.4M | $-3.2M | $-2.2M | $-1.9M | $-3.1M | $3.5M |
| Income Tax Expense | $200 | — | — | — | — | $200 | $481 | $200 |
| Net Income | $-2.6M | $-3.7M | $-2.4M | $-3.2M | $-2.2M | $-1.9M | $-3.1M | $3.5M |
| Net Margin | -1,379.6% | -3,075.4% | -206.9% | -2,781.5% | -354.1% | -1,986.8% | -3,426.2% | 46.1% |
| EPS (Basic) | $-0.32 | $-0.54 | $-0.42 | $-0.59 | $-0.41 | $-0.35 | $-0.57 | $0.66 |
| EPS (Diluted) | $-0.32 | $-0.54 | $-0.34 | $-0.59 | $-0.41 | $-0.35 | $-0.56 | $0.66 |
| Shares Outstanding (Basic) | 8.2M | 6.8M | 5.4M | 5.4M | 5.4M | 5.3M | 5.3M | 5.3M |
| Shares Outstanding (Diluted) | 8.2M | 6.8M | 5.7M | 5.4M | 5.4M | 5.3M | 5.3M | 5.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |